CORE POSITIONING

Despite the rapid growth in the field of antibody-drug conjugates (ADCs), there remains a significant gap in innovation when it comes to ADC target selection.

Most ADCs in clinical trials focus on a limited set of well-validated tumor antigens, such as HER2, Nectin4, Trop2, DLL3, and FRa. As a result, many tumor-enriched cell surface proteins remain untapped, offering potential for the development of new and more effective ADC therapies for cancer patients.